Michael Vittone, MD
Ophthalmology · Latrobe, PANPI 1104879238
Payments from drug & device makers
Across 17 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$106
- Novartis$75
- Dompe US, Inc.$31
- Sun Pharmaceutical Industries Inc.$29
- Carl Zeiss Meditec AG$19
- Harrow Eye, LLC$19
- plus $80 from 5 others
What the payments were for
- Food & beverage$33895%
- Gifts$195%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 4 | $106 |
| Novartis | 4 | $75 |
| Dompe US, Inc. | 1 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $29 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Harrow Eye, LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Thea Pharma Inc. | 1 | $17 |
| Alcon | 1 | $14 |
| Biotissue Holdings Inc. | 1 | $13 |
How this compares
$358 in reported general payments places this provider in the 25th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 82 | $87,934 |
| RestasisCyclosporine | 61 | $76,414 |
| Cyclosporine | 66 | $46,226 |
| LumiganBimatoprost | 78 | $36,581 |
| Prednisolone Acetate | 581 | $23,456 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 96 | $17,960 |
| MieboPerfluorohexyloctane/Pf | 19 | $14,158 |
| Ketorolac Tromethamine | 639 | $14,087 |
| Latanoprost | 850 | $10,328 |
| Travoprost | 48 | $9,069 |
| Alphagan PBrimonidine Tartrate | 17 | $7,906 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $7,522 |
| Timolol Maleate | 229 | $6,130 |
| Ofloxacin | 498 | $5,596 |
| VyzultaLatanoprostene Bunod | 11 | $3,389 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Latrobe
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.